Literature DB >> 12941150

Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients.

Cécile Contin1, Vincent Pitard, Yahsou Delmas, Nadège Pelletier, Thierry Defrance, Jean-François Moreau, Pierre Merville, Julie Déchanet-Merville.   

Abstract

CD40/CD154 interaction is essential for both humoral and cellular immune response. We investigated whether this interaction could be altered in patients with kidney failure who are known to present an impaired immune response. To that aim, we measured the levels of the soluble form of CD40 (sCD40), which is known to interfere with CD40/CD154 interaction, in 43 chronic renal failure patients, 162 hemodialysed patients, and 83 healthy donors. Uraemic and haemodialysed patients presented a three- and fivefold increase, respectively, of the antagonist soluble form of CD40 in their serum, when compared to healthy subjects. Serum sCD40 levels correlated with those of creatinine in uraemic non-haemodialysed patients. While sCD40 is widely excreted in urine of healthy individuals, it is not eliminated by dialysis sessions on classic membranes. The return to a normal kidney function in nine haemodialysed patients who received renal transplantation, leads to a rapid decrease of serum sCD40 levels. This natural sCD40 exhibited multimeric forms and was able to inhibit immunoglobulin production by CD154-activated B lymphocytes in vitro. Furthermore, the positive correlation we observed between the serum levels of sCD40 and the deficient response to hepatitis B vaccination in uraemic patients suggests that sCD40 also compromises the humoral response in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941150      PMCID: PMC1783029          DOI: 10.1046/j.1365-2567.2003.01716.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  48 in total

Review 1.  How B and T cells talk to each other.

Authors:  E A Clark; J A Ledbetter
Journal:  Nature       Date:  1994-02-03       Impact factor: 49.962

2.  Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients.

Authors:  P Jungers; P Chauveau; A M Couroucé; P Devillier; J L Excler; F Bailleux; P Saliou
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

3.  CD40 preferentially costimulates activation of CD4+ T lymphocytes.

Authors:  M Cayabyab; J H Phillips; L L Lanier
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

4.  CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM.

Authors:  J P DiSanto; J Y Bonnefoy; J F Gauchat; A Fischer; G de Saint Basile
Journal:  Nature       Date:  1993-02-11       Impact factor: 49.962

5.  B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40.

Authors:  C van Kooten; C Gaillard; J P Galizzi; P Hermann; F Fossiez; J Banchereau; D Blanchard
Journal:  Eur J Immunol       Date:  1994-04       Impact factor: 5.532

Review 6.  The CD40 antigen and its ligand.

Authors:  J Banchereau; F Bazan; D Blanchard; F Brière; J P Galizzi; C van Kooten; Y J Liu; F Rousset; S Saeland
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 7.  The role of CD40 in the regulation of humoral and cell-mediated immunity.

Authors:  F H Durie; T M Foy; S R Masters; J D Laman; R J Noelle
Journal:  Immunol Today       Date:  1994-09

8.  Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction.

Authors:  D Gray; P Dullforce; S Jainandunsing
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

Review 9.  Defective expression of CD40 ligand on T cells causes "X-linked immunodeficiency with hyper-IgM (HIGM1)".

Authors:  R A Kroczek; D Graf; D Brugnoni; S Giliani; U Korthüer; A Ugazio; G Senger; H W Mages; A Villa; L D Notarangelo
Journal:  Immunol Rev       Date:  1994-04       Impact factor: 12.988

10.  Interleukin 10 (IL-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes.

Authors:  A C Fluckiger; P Garrone; I Durand; J P Galizzi; J Banchereau
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

View more
  17 in total

1.  Effects of environmentally-relevant levels of perfluorooctane sulfonate on clinical parameters and immunological functions in B6C3F1 mice.

Authors:  Patricia A Fair; Erin Driscoll; Meagan A M Mollenhauer; Sarah G Bradshaw; Se Hun Yun; Kurunthachalam Kannan; Gregory D Bossart; Deborah E Keil; Margie M Peden-Adams
Journal:  J Immunotoxicol       Date:  2011-01-24       Impact factor: 3.000

2.  Usefulness of preoperative estimated glomerular filtration rate to predict complications after curative gastrectomy in patients with clinical T2-4 gastric cancer.

Authors:  Yuri Tanaka; Mitsuro Kanda; Chie Tanaka; Daisuke Kobayashi; Akira Mizuno; Naoki Iwata; Masamichi Hayashi; Yukiko Niwa; Hideki Takami; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2016-10-12       Impact factor: 7.370

Review 3.  Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Authors:  Rituparna Chakrabarti; Bhavya Kapse; Gayatri Mukherjee
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-07

Review 4.  Hepatitis B vaccine by intradermal route in non responder patients: an update.

Authors:  Martina Filippelli; Elena Lionetti; Alessia Gennaro; Angela Lanzafame; Teresa Arrigo; Carmelo Salpietro; Mario La Rosa; Salvatore Leonardi
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

5.  A functional TNFRSF5 gene variant is associated with risk of lymphoma.

Authors:  Christine F Skibola; Alexandra Nieters; Paige M Bracci; John D Curry; Luz Agana; Danica R Skibola; Alan Hubbard; Nikolaus Becker; Martyn T Smith; Elizabeth A Holly
Journal:  Blood       Date:  2008-02-20       Impact factor: 22.113

6.  Effect of CD40 and sCD40L on renal function and survival in patients with renal artery stenosis.

Authors:  Steven T Haller; Philip A Kalra; James P Ritchie; Tina Chrysochou; Pamela Brewster; Wencan He; Haifeng Yu; Joseph I Shapiro; Christopher J Cooper
Journal:  Hypertension       Date:  2013-02-11       Impact factor: 10.190

7.  Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.

Authors:  Susana G Melendreras; Pablo Martínez-Camblor; Aurora Menéndez; Cristina Bravo-Mendoza; Ana González-Vidal; Eliecer Coto; Carmen Díaz-Corte; Marta Ruiz-Ortega; Carlos López-Larrea; Beatriz Suárez-Álvarez
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

8.  Serum soluble CD40 is associated with liver injury in patients with chronic hepatitis B.

Authors:  Hong-Hui Shen; Bing-Ke Bai; Ya-Qing Wang; Guang-DE Zhou; Jun Hou; Yan Hu; Jing-Min Zhao; Bao-Sen Li; Hai-Li Huang; Pan-Yong Mao
Journal:  Exp Ther Med       Date:  2015-01-14       Impact factor: 2.447

9.  The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer.

Authors:  Annette Torgunrud; Hanna Abrahamsson; Sebastian Meltzer; Arne Mide Solbakken; Kjersti Flatmark; Svein Dueland; Kine Mari Bakke; Paula Anna Bousquet; Anne Negård; Christin Johansen; Lars Gustav Lyckander; Finn Ole Larsen; Jakob Vasehus Schou; Kathrine Røe Redalen; Anne Hansen Ree
Journal:  Br J Cancer       Date:  2021-04-09       Impact factor: 7.640

10.  Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients.

Authors:  Alicja E Grzegorzewska
Journal:  Hepat Mon       Date:  2012-11-14       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.